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This commentary refers to ‘Characteristics of heart
failure patients associated with good and poor response
to cardiac resynchronization therapy: a PROSPECT
(Predictors of Response to CRT) subanalysis’†, by R.J.
van Bommel et al., on page 2470
Cardiac resynchronization therapy (CRT) is the most successful
therapy in treating chronic heart failure patients since the introduc-
tion of b-blockers, angiotensin-converting enzyme (ACE) inhibi-
tors, and spironolactone into the therapeutic regimen. Recent
studies (REVERSE, MADIT-CRT) will probably expand the indi-
cation for CRT to mild and asymptomatic heart failure patients
[New York Heart Association (NYHA) functional class I and II],
an enormous task for physicians and healthcare providers. CRT
with current indications appears to improve the clinical status in
70% of patients. This compares well with the effects of treat-
ments of chronic and life-threatening diseases in other medical
fields.
However, indications for CRT are currently based to a large
degree on QRS width in an attempt to detect mechanical dyssyn-
chrony under the assumption that correction of dyssynchrony is
the main mechanism of action. The idea behind the original Predic-
tors of Response to CRT (PROSPECT) study was to identify in a
non-randomized observational design the predictive value of pre-
defined echocardiographic parameters of mechanical dyssynchrony
with regard to clinical and left ventricular mechanical outcome
after CRT.1 Twelve previously published parameters of dyssyn-
chrony, both conventional and tissue Doppler-based methods,
had finally been used in 426 CRT patients at 53 centres. Consider-
ing the intended purpose of the PROSPECT study, the overall
results were not encouraging, with no single echocardiographic
dyssynchrony parameter being highly predictive of the CRT
response at follow-up. There seemed to be no ‘holy grail’ of echo-
cardiographic dyssynchrony parameter which by itself could be
used for decision making regarding CRT.
Is this the end of the ‘mechanical dyssynchrony’ hypothesis? Is
echocardiography useless in predicting CRT respsonse despite
numerous single-centre studies showing high sensitivity and speci-
ficity? Immediately after publication of the PROSPECT results,
numerous concerns regarding the design of the study and the
way in which it was conducted were raised, especially regarding
patient selection as well as echocardiographic assessment. Con-
cerning patient selection, 20.2% had a left ventricular ejection frac-
tion (LVEF) .35%, and 37.8% had a left ventricular end-diastolic
diameter (LVEDD) ,65 mm, which ultimately raised the question
of how reverse remodelling could be achieved in a non-dilated
heart.2 This, together with a substantial interobserver variability
and large percentage of non-assessable echocardiographic
studies, indicated a lack of standardized data acquisition and analy-
sis. In addition, tissue Doppler imaging (TDI) data were obtained
using echo machines from thee different ultrasound providers
without standardization of frame rates, and three different soft-
ware programs were used for offline data analysis. Furthermore,
there was no information on left ventricular lead placement and
percentage biventricular pacing. Taken together, important techni-
cal limitations as well as suboptimal patient selection may impor-
tantly confound and limit the interpretation of the initial
PROSPECT study results.
Van Bommel et al. have performed a subgroup analysis of 286 of
the total of 498 patients which had initially been enrolled into
PROSPECT;3 426 of those had been originally analysed in the
main PROSPECT study after 31 early exits and the exclusion of
41 patients with narrow QRS (,130 ms). Eventually, this substudy
analysed 57% of the total PROSPECT population, further excluding
15 patients who died, 18 patients who had been lost for the
6-month follow-up visit, and 44 patients with incomplete data
from the 6-month follow-up visit, thus ending up with 286 patients
with a complete data set and paired left ventricular end-systolic
volume (LVESV) measurements. Overall, this represents quite a
substantial reduction compared with the 498 originally enrolled
patients.
In order to dissect the response to CRT, the authors grouped
patients according to both a combined clinical and a pure echocar-
diographic response. Echocardiographically, subgroups were
formed consisting of so-called ‘super-responders’ with a reduction
of .30% in LVESV; ‘responders’ with a 15–29% reduction in
LVSEV; ‘non-responders’ without evidence of reverse remodelling
and reduction of LVESV between 0 and 14%; and ‘negative respon-
ders’ with echocardiographic signs of disease progression despite
CRT with an increase in LVESV after 6 months. Clinically, they
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grouped their patients according to a combined clinical composite
score (CCS) measured 6 months after implantation. A positive
clinical response was defined as the patient surviving and not
being hospitalized for heart failure, demonstrating improvement
in NYHA class at the last observation carried forward, or having
moderate or marked improvement in patient global assessment
score at the last observation carried forward. Finally, using both
clinical and echocardiographic data, they formed three subgroups
according to clinical and/or echocardiographic response: (1)
þ/þ responders (improved CCS and a reduction in LVESV
.15%); (2) þ/2 responders (improved CCS or a reduction in
LVESV .15%); and (3) 2/2 responders (no improvement in
CCS and no reduction in LVESV .15%).
When looking at the pure mechanistic outcome, i.e. echocardio-
graphic parameters of left ventricular structure and function, of the
286 studied patients, 56.3% had significant evidence of reverse
remodelling. It is well known that some patients have an extraordi-
narily good response to CRT (the so-called ‘super-responders’)
with a .30% reduction of LVESV. Compared with patients who
deteriorated, the ‘negative responders’, it is not surprising that sig-
nificantly more patients had a non-ischaemic aetiology (resulting in
less scar burden and more viable myocardium for reverse remo-
delling) in the ‘super-responder’ subgroup. These patients also
less commonly had a history of ventricular tachycardia, which
might be explained by the underlying disease aetiology and the
disease state, with significantly fewer patients in NYHA class IV
in this subgroup. Interestingly, at baseline ‘super-responders’
were significantly more dyssynchronous than the ‘negative respon-
ders’, as evidenced by a larger interventricular mechanical delay
(IVMD; 55+35 ms vs. 25+ 39 ms, P ¼ 0.0002) and septal to
lateral delay on tissue Doppler (68+44 ms vs. 44+ms; P ¼
0.0022). This observation is in line with a recent report in the
CARE-HF trial, showing that patients with wide QRS and and
IVMD .49 ms treated with CRT showed superior survival.4
Indeed, pathophysiologically, IVMD reflects left to right heart inter-
action and is useful only in patients with a broad QRS complex;
conversely, IVMD is virtually absent in patients with a narrow
QRS complex.5 Importantly, both echocardiographic parameters
can be measured relatively easily, and IVMD is one of the most
robust parameters with respect to interobserver variability.
Hence, the findings of van Bommel and colleagues3 support for
the first time in a multicentre environment with .53 centres
the concept that we are in fact treating mechanical dyssynchrony
with CRT.
When looking at the CCS after 6 months, a greater percentage
of patients showed signs of clinical benefit than evidence of reverse
remodelling. In fact, 209 out of 286 patients (73%) had a positive
CCS, while only 114 patients showed a clinical response without
significant change in LVSEV (40%). This is remarkable but not
very surprising. CRT can stabilize patients with advanced heart
failure, i.e. ‘non-progressors’; however, these patients do not
necessarily have signs of reverse remodelling, possibly due to an
already too advanced disease and/or scar burden. Yet, clinical
improvement is of great interest for the patient and should
therefore importantly be counted as therapeutic success. This is
why withholding CRT from a patient with a QRS .130 ms just
because of a lack of echocardiographic signs of dyssynchrony
does not seem to be justified, merely based on a slightly inferior
prediction of reverse remodelling.
Taken together, the current substudy of PROSPECT by van
Bommel et al.3 adds important evidence to the current literature.
However, even after this careful examination of the available data
within the PROSPECT cohort and a positive correlation between
baseline echocardiographic dyssynchrony and reverse remodelling,
the presented evidence does not appear to be strong enough to
change current clinical practice and exclude patients fulfilling
current guidelines for CRT simply based on lack of dyssynchrony
on echocardiography. Other limitations, which were equally
inherent to the original PROSPECT trial, are also problematic
for the current substudy. Importantly, the short-term follow up
of only 6 months is far too little to assess the entire effect of
CRT on remodelling and, eventually, morbidity and mortality.
Indeed, had CARE-HF been stopped after 6 months, no significant
effect on morbidity and mortality would have been observed; fur-
thermore, ongoing reverse remodelling was evident even after 18
months of follow-up in the CRT substudy.6 As the authors state,
the goal is to measure the impact of mechanical dyssynchrony
on clinical outcome after CRT. In the end, this question can only
be answered by an adequately powered randomized clinical trial.
Such a trial is already underway investigating the impact on
morbidity and mortality of baseline dyssynchrony in patients with
symptomatic heart failure, LVEF ,35% and a QRS ,130 ms
(Echocardiography Guided Cardiac Resynchronization Therapy,
EchoCRT, NCT00683696).
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